Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v7-FR
Language French French
Date Updated 2019-10-26 2019-10-26
Drug Identification Number 02361671 02361671
Brand name RAPAFLO RAPAFLO
Common or Proper name RAPAFLO 8MG RAPAFLO 8MG
Company Name ALLERGAN INC ALLERGAN INC
Ingredients SILODOSIN SILODOSIN
Strength(s) 8MG 8MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL
Packaging size 90 90
ATC code G04CA G04CA
ATC description DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2019-09-23 2019-09-23
Actual start date 2019-10-11 2019-10-11
Estimated end date 2019-10-28 2019-10-28
Actual end date 2019-10-25 2019-10-25
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments
Health Canada comments